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Abstract
Background: A prospective, randomized study was conducted to evaluate the efficacy and
tolerability of oral propafenone and quinidine for the conversion of paroxysmal atrial fibril-
lation (AF).
Methods: Eighty one consecutive patients (female/male 46/35; mean age 64.0 ± 11.6),
admitted to hospital with AF lasting no longer than 48 hours, were randomized in terms of
their pharmacological therapy. Forty three patients (55%) were randomly assigned to Group I
and received propafenone 600 mg orally as the initial therapy, with an additional dose of 300 mg
after eight hours, if the sinus rhythm had not been restored by then. Thirty eight patients (45%)
(Group II) received 1 mg digoxin IV followed by an oral loading of quinidine (400 mg followed
by 200 mg every two hours).
Results: The conversion rate assessed after 24 hours was the same in both groups (Gr. I vs.
Gr. II: 90.7 vs. 91.4%), with the same number of mild side effects (Gr. I vs. Gr. II: 37.2% vs.
45.7%). No life-threatening adverse events were reported. Propafenone achieved a higher
efficacy rate during the first eight hours (83.3 vs. 54.3%; p = 0.01), with a significantly
shorter time required to sinus rhythm recovery throughout the study period, with a median
time of 165 min (95% confidence interval 120–278) vs. 360 min (95% confidence inerval
298–650; p < 0.05). There was some indication of greater effectiveness of propafenone than
quinidine in early sinus rhythm restoration in patients with: no structural heart disease, in
those with an AF duration shorter than 12 hours, and in patients with an ejection fraction > 55%.
Conclusions: Although both drugs revealed the same effectiveness, the conversion to sinus
rhythm in the group treated with propafenone was observed more quickly despite the longer
paroxysmal AF episode duration. (Cardiol J 2009; 16, 6: 521–527)
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Introduction
Atrial fibrillation (AF) has been considered
a significant medical, social, and pharmaco-econo-
mic problem in recent decades. Prolonged life-span
among patients with cardiovascular disease, relat-
ed to higher quality medical care, has resulted in
more new cases of arrhythmia [1]. Despite the new
strategies involved in the medical therapy of AF,
supported by new technologies and the achieve-
ments of the pharmacological industry, every year
brings many new hospital admissions related to the
appearance of arrhythmia or its complications. De-
spite advances in medical therapy, most patients
with paroxysmal AF are managed with medication [2].
The main goal of the medical approach is to restore
sinus rhythm (SR), relieve symptoms and reduce
the risk of thromboembolic complications. There is
no clear-cut superiority of any of the antiarrhyth-
mic agents for patients with new-onset AF [3]. The
efficacy of particular medical agents, usually as-
sessed within the first 24 hours of medical thera-
py, are almost equal for all agents approved for phar-
macological cardioversion. The main goal of the
medical approach for patients with new-onset AF
without significant hemodynamic disturbances is to
shorten the time to SR restoration, as well as the
safety of the proposed therapy. The goal of our study
was to investigate the efficacy and tolerability of
standard oral pharmacological therapies in paroxys-
mal AF involving propafenone and quinidine.
Methods
Inclusion and exclusion criteria
This prospective, randomized, single-center
study covered consecutive patients with sympto-
matic recent onset AF defined as < 48 hours dura-
tion. The onset of arrhythmia was considered as the
abrupt, well-defined historical appearance of palpi-
tation, with subsequent electrocardiographic evi-
dence of AF. Patient inclusion criteria were: age
from 18 to 85 years, mean ventricular rate above
70 beats per minute (calculated over at least 30 R-R
cycles), as well as New York Heart Association
(NYHA) functional class < II. Exclusion criteria
were: documented intolerance, ineffectiveness or
contraindications for study drugs, thyroid dysfunc-
tion, myocardial infarction in the three months pre-
ceding the study, acute myocarditis, cardiac surgery
in the 30 days prior to the study, hemodynamic in-
stability defined as symptomatic heart failure or
hypotension (systolic pressure < 90 mm Hg), sys-
temic hypertension not responding to treatment
(diastolic pressure > 115 mm Hg), valvular heart
disease qualified for surgical treatment, R-R inter-
vals exceeding more than 3 s, ventricular rhythm
below 70/min (unrelated to drugs reducing ventricu-
lar rhythm), bundle branch block, electrocardiogram
(ECG) evidence (past or present) of ventricular pre-
excitation syndrome, QT segment prolongation
(a corrected QT interval of more than 480 ms or an
uncorrected QT interval of more than 500 ms), hy-
pokalemia (serum potassium level < 3.5 mmol/L),
pregnancy and lactation, liver, kidney or central
nervous system damage, advanced chronic lung dis-
ease, or malignancy. Patients were also excluded
from the study if they had been medicated with dig-
italis or subjected to any antiarrhythmic therapy in
the previous 24 hours.
All selected patients were advised of the aim
and course of the study and gave their written in-
formed consent prior to inclusion in the trial.
The investigations, approved by the Ethics
Committee, were carried out by the Chair and De-
partment of Cardiology at the Medical University
of Warsaw.
Study protocol
From 2003 until 2005, consecutive patients
admitted to our department with symptomatic re-
cent onset of AF, and who fulfilled the inclusion
criteria, were recruited for the study. Eligible pa-
tients qualified for pharmacological cardioversion of
arrhythmia were randomly assigned to groups.
Group I received propafenone 600 mg orally as the
initial therapy and an additional dose of 300 mg af-
ter eight hours, if the SR had not been restored by
then. Group II received digoxin 1 mg IV followed
by an oral loading of quinidine (400 mg followed by
200 mg every two hours, with the total dose not
exceeding 1400 mg). The exact time of SR restora-
tion was estimated by 24-hour Holter ECG moni-
toring. The duration of all treatments did not ex-
ceed 24 hours. During the study patients were bed
resting, continuously monitored and arterial blood
pressure was evaluated every hour. Twelve leads
ECG (50 mm/s paper speed) were recorded prior
to the application of the first dose of the study drug,
as well as at the 3rd, 6th, 12th and 24th hour of the
study. PR, QRS and QTc intervals were measured
according to the Bazet formula, in order to evalu-
ate the time of onset of the effects of the propaf-
enone and quinidine, respectively. SR restoration
was also confirmed by standard ECG. At admission
two-dimensional and M-mode echocardiograms
were recorded to evaluate left atrial dimension, left
ventricular end-systolic and end-diastolic diame-
523
Dariusz Kosior et al., Propafenone vs. quinidine for recent onset AF
www.cardiologyjournal.org
ters, as well as left ventricular ejection fraction. All
measurements taken complied with the relevant
standards of the American Society of Echocardiog-
raphy [4].
Safety protocol
Safety was assessed by recording the appear-
ance of clinical proarrhythmic and hemodynamic
adverse events, both those reported by the patients
and those observed by the investigators. A clinical
adverse event was defined as a cardiac or non-car-
diac undesirable or unusual experience reported
by a patient following study drug administration.
A proarrhythmic event was defined as the appear-
ance of a new tachyarrhythmia of any origin and/or
new bradyarrhythmia resulting from nodal dysfunc-
tion, atrioventricular or other conduction disturbanc-
es [5, 6]. Hemodynamic adverse events were con-
sidered as any changes in arterial blood pressure or
heart failure exacerbation not related to proarrhyth-
mic events that required medical intervention.
Statistical analysis
Summary data is expressed as means ± stand-
ard deviation (SD) or absolute numbers and percent-
ages of patients. Analyses were performed in ac-
cordance with the intention-to-treat principle. The
cumulative risk of AF recurrence was estimated
with the Kaplan-Meier product-limit method. The
differences between treatment groups were as-
sessed by means of the log-rank test. The early SR
restoration predictability was developed based on
generalized additive logistic regression. P-value for
interaction term was used to assess the significance
of the difference in treatment effect. P value < 0.05
was considered statistically significant.
Results
Study group profile and
sinus rhythm restoration
The study population consisted of 81 consecu-
tive patients (female/male 46/35; mean age 64.0 ±
± 11.6; 30–83 years) admitted to emergency room
with new onset of AF lasting no longer than
48 hours (mean duration time of arrhythmia 12.3 ±
± 11.1 h; 1–47 h). All patients qualified for phar-
macological conversion of AF were randomly as-
signed to two different medical therapy protocols.
Forty three patients (55%; female/male 22/21; mean
age 62.1 ± 10.7 years; Group I) received propa-
fenone 600 mg orally as the initial therapy. Within
the first eight hours, SR was restored in 36 patients
(83.3%); seven patients received an additional dose
of propafenone 300 mg. At the end of the observa-
tional period, 39 study patients (90.7%) were free
of arrhythmia with propafenone mean doses of 676.7 ±
± 132.4 mg required for this success rate. Thirty
eight patients (45%; female/male 16/19; mean age
66.1 ± 12.4 years; Group II) received 1 mg digoxin
IV as an initial therapy, which was followed by an
oral loading of quinidine (400 mg followed by
200 mg every two hours with the total dose not ex-
ceeding 1400 mg). After eight hours 54.3% of patients
treated with quinidine were free from arrhythmia.
Recommended therapy was able to restore SR in
35 patients (91.4%) within the first 24 hours of fol-
low-up with quinidine mean doses of 830 ± 430 mg.
There was no significant difference in the efficacy
of the drugs being studied after 24 hours of follow-up
(90.1% vs. 91.4%; p = 0.78); although propafenone
achieved a higher efficacy rate during the first eight
hours (83.3% vs. 54.3%; p < 0.01), with a significantly
shorter time required to SR recovery throughout
the study period, with median time 165 min (95%
confidence interval 120–278 min) vs. 360 min (95%
confidence interval 298–650 min; p < 0.05). Table 1
summarizes the clinical and echocardiographic char-
acteristics of both study groups at the baseline.
Figure 1 shows the sinus rhythm conversion rate
for both study groups.
Hemodynamic profile and
adverse events of study drugs
No life-threatening adverse events were re-
ported during the follow-up. The same number of
mild side effects was noted in both groups (Gr. I vs.
Gr. II: 37.2% vs. 45.7%; p = 0.56). The potential
proarrhythmic effect was observed in 16 study pa-
tients; nine (19.6%) on propafenone and seven
(20.0%) on quinidine. In one patient (2%) signifi-
cant bradycardia (< 35’/min) was observed which
required atropine administration during propa-
fenone therapy. One patient (2%) in the quinidine
group suffered from nausea and vomiting, and re-
quired drug discontinuation. Both drugs led to sig-
nificant blood pressure and heart rate reduction, but
within satisfactory ranges, and did not call for me-
dical intervention. No case of significant heart
failure exacerbation was observed in any patient
(Tables 2, 3). The QRS and QTc lengths were com-
parable between the study groups in each point of
the study. QRS complex duration became signifi-
cantly longer in the propafenone group starting from
the 6th hour of therapy (79 ± 12 vs. 86 ± 8 ms;
p < 0.05), but still remained within normal ranges.
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Applying logistic regression analysis, we at-
tempted an examination of the impact of the pa-
tient’s age and gender on the cardioversion’s early
success, defined as SR restoration up to eight hours
of therapy. No statistically significant correlation
between the variables in question and the treatment
success rate was established (p > 0.62 and p > 0.87,
respectively). To eliminate the impact of the above
mentioned variables on the correlation between eval-
uated parameters, we decided to take them into ac-
count while developing the test models.
To find the group of patients in which one of
the investigated treatment strategies is better, we
ran a series of logistic regression models in subsets
of patients with and without factors of interest such
as assessed at the baseline clinical and echocardio-
graphic parameters. As shown in Figure 2, there
were some trends indicating better effectiveness of
propafenone than quinidine in early sinus rhythm
restoration in patients with: no structural heart di-
sease, in those with AF duration shorter than
12 hours, and in patients with ejection fraction
> 55%. However, these trends did not reach signi-
ficance (an overlap of confidence intervals between
two subgroups for each tested variable). We also
found no significant interaction term, but it could
be due to our relatively small sample size. The dif-
ference in treatment effect could be further inves-
tigated in studies with a higher sample size.
Discussion
The main end-point of our study was to evalu-
ate the efficacy and safety profile of an acute oral
loading dose of propafenone in restoring SR in pa-
tients with recent onset of AF compared to quini-
dine preceded by digoxin IV bolus in pharmacolog-
ical cardioversion.
After a 24 hour follow-up period, the effective-
ness of both strategies was above 90% and almost
Table 1. The study groups’ baseline characteristics.
Parameter Propafenone Quinidine Significance
Number of patients 46 35 NS
Age (years) 62.1 ± 10.7 66.1 ± 12.4 NS
Gender:
Female 22 (51%) 16 (46%) NS
Male 21 (49%) 19 (54%) NS
Mean AF duration [h] 14.5 ± 13.0 9.7 ± 7.7 0.05
First AF episode 14 (32.6%) 12 (34.2%) NS
History of paroxysmal AF (years) 4.7 ± 4.5 5.6 ± 3.7 NS
AF etiology:
Ischemic heart disease 26 (60.5%) 17 (48.6%) NS
Myocardial infarction 8 (18.6%) 6 (17.1%) NS
CABG 1 (2.3%) 0 (0.0%) NS
Systemic hypertension 25 (58.1%) 19 (54.3%) NS
No structural heart disease 36 (83.7%) 27 (77.1%) NS
Echocardiographic parameters:
LAsax. [mm] 43.9 ± 5.0 40.0 ± 3.0 NS
LVEDD [mm] 51.0 ± 5.0 51.0 ± 5.0 NS
LVEF (%) 56.4 ± 3.8 52.5 ± 6.2 NS
AF — atrial fibrillation; CABG — coronary artery bypass grafting; LAsax. — antero-posterior left atrial diastolic diameter; LVEDD — left ventricle
end-diastolic diameter; LVEF — left ventricular ejection fraction
Figure 1. Kaplan-Meier’s curves presenting the efficacy
of both therapies during 24 hours follow-up.
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equal, as previously discussed [7–9]. However, our
data confirms the high efficacy of a single oral loading
dose of 600 mg propafenone, with an 83% conver-
sion rate within the first eight hours of therapy. An
additional 300 mg of propafenone administered eight
hours after the initial dose did not significantly in-
crease the success rate with respect to the other drug.
Thus, a single 600 mg dose of propafenone is
effective in most patients with recent onset of AF.
The efficacy rate was affected by some parameters,
such as no evidence of structural heart disease,
preserved left ventricular ejection fraction as well
as AF duration shorter than 12 hours. Nevertheless,
the homogeneity of our study population and rela-
tively small number of patients with heart disease
other than systemic hypertension did not allow us
to draw any definite conclusions in this respect. Our
study confirmed the high efficacy rate of quinidine.
Digoxin given intravenously due to controlled ven-
tricular response during pharmacotherapy with
quinidine, a drug with potential cholinolytic effect,
has no proven efficacy in SR restoration [10]. Some
reported data suggests a high efficacy of the IV ad-
ministration of digoxin. A higher conversion rate
was noted not only during combination with quini-
dine, but also with other compounds such as propa-
Table 2. Side effects.
Propafenone Quinidine Significance
No. of patients (%)
Number of patients 46 35
Death – – NS
Bleeding complications – – NS
Thromboembolic complications:
Ischemic stroke – – NS
Pulmonary embolism – – NS
Proarrhythmia: NS
Ventricular tachycardia 1 (2.3%) 1 (2.9%) NS
Bigeminy/trigeminy 4 (9.3%) 4 (11.4%) NS
QTc prolongation – – NS
Atrial flutter 4 (9.3%) 2 (5.7%) NS
Bradycardia 2 (4.7%) –
Somatic symptoms: NS
Headache 2 (4.7%) 4 (11.4%) NS
Abdominal pain/dyspeptic symptoms 2 (4.7%) 5 (14.3%) NS
Hypotension – – NS
Pacemaker implantation – – NS
Total 15 (37.2%) 16 (45.7%) NS
Table 3. Hemodynamic profile of study drugs.
Before sinus After sinus Significance
rhythm restoration  rhythm restoration
Heart rhythm [beats/min] Propafenone 131 ± 21.1 74.6 ± 12.4 0.0001
Quinidine 124 ± 26.3 75.3 ± 11.8 0.0001
NS NS
Systolic blood pressure [mm Hg] Propafenone 137 ± 26.3 126 ± 10 0.02
Quinidine 140 ± 18.4 125 ± 12 0.0003
NS NS
Diastolic blood pressure [mm Hg] Propafenone 85.2 ± 13.4 79.8 ± 5.91 0.02
Quinidine 87.1 ± 8.51 78.7 ± 5.94 0.0001
NS NS
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fenone [11, 12]. However, due to the potential high-
er rate of proarrhythmic effects and poor evidence
supporting a direct antiarrhythmic effect of digoxin,
such a combination is now not recommended [10].
The other very important aspect of our study
was the tolerability of the proposed therapy. Be-
cause of the good short-term prognosis in patients
with recent onset AF, safety is an important aspect
in the management of arrhythmia. Despite obvious
evidence supporting the use of Class IC represent-
atives in the restoration and maintenance of SR,
several proarrhythmic events have been reported,
mostly during long-term therapy [13–15]. Less at-
tention was paid to the possible proarrhythmic ef-
fects of propafenone during acute treatment and
there are only a few clinical controlled trials available,
with small numbers of patients studied [12, 16–18].
No life-threatening adverse effects were reported
during our study. There was one case of bradycar-
dia and non-sustained ventricular tachycardia with
mild intensity which constituted no major clinical
problems. The therapy was well tolerated without
any somatic problems related to the drug.
Our results confirm previously reported data
supporting the high efficacy and rapid response to
an oral loading dose of propafenone. We think that
very good tolerability of 600 mg propafenone given
orally as a single dose, as well as the low and ac-
ceptable rate of proarrhythmic effect, allow us to
recommend this kind of therapy for patients with
Figure 2. Parameters affecting early sinus rhythm restoration; AF — atrial fibrillation; LA — antero-posterior left atrial
diastolic diameter; LVEDD — left ventricle end-diastolic diameter; LVEF — left ventricular ejection fraction;
OR — odds ratio; CI — confidence interval.
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paroxysmal AF. In patients with high risk of pro-
arrhythmia, propafenone therapy should be initiated
in-hospital manner.
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